Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)
This trial is active, not recruiting.
|Treatment||pregabalin (lyrica) capsule|
|Start date||February 2011|
|End date||June 2017|
|Trial size||4000 participants|
|Trial identifier||NCT01256593, A0081261|
The objective of this Investigation is to evaluate the safety and efficacy of Lyrica in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Lyrica will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.
Change in Clinical Global Impression of Clinical Condition (CGI-C) From Baseline at Month X
time frame: 13 weeks
Male or female participants of any age.
Inclusion Criteria: - Patients need to be administered Lyrica® in order to be enrolled in the surveillance. Exclusion Criteria: - Patients not administered Lyrica®.
|Official title||Drug Use Investigation Of Lyrica(Regulatory Post Marketing Commitment Plan)|
|Description||All the patients whom an investigator prescribes the first Lyrica® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.|
Call for more information